COVID‐19 diagnosis and management: a comprehensive review
- 13 May 2020
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 288 (2), 192-206
- https://doi.org/10.1111/joim.13091
Abstract
Severe acute respiratory syndrome coronavirus (SARS‐CoV)‐2, a novel coronavirus from the same family as SARS‐CoV and Middle East respiratory syndrome coronavirus, has spread worldwide leading the World Health Organization to declare a pandemic. The disease caused by SARS‐CoV‐2, coronavirus disease 2019 (COVID‐19), presents flu‐like symptoms which can become serious in high‐risk individuals. Here we provide an overview of the known clinical features of and treatment options for COVID‐19. We carried out a systematic literature search using the main online databases (PubMed, Google Scholar, MEDLINE, UpToDate, Embase and Web of Science) with the following keywords: ‘COVID‐19’, ‘2019‐nCoV’, ‘coronavirus’ and ‘SARS‐CoV‐2’. We included publications from 1 January 2019 to 3 April 2020 which focused on clinical features and treatments. We found that infection is transmitted from human to human and through contact with contaminated environmental surfaces. Hand hygiene is fundamental to prevent contamination. Wearing personal protective equipment is recommended in specific environments. The main symptoms of COVID‐19 are fever, cough, fatigue, slight dyspnoea, sore throat, headache, conjunctivitis and gastrointestinal issues. Real‐time PCR is used as a diagnostic tool using nasal swab, tracheal aspirate or bronchoalveolar lavage samples. Computed tomography findings are important for both diagnosis and follow‐up. To date, there is no evidence of any effective treatment for COVID‐19. The main therapies being used to treat the disease are antiviral drugs, chloroquine/hydroxychloroquine and respiratory therapy. In conclusion, although many therapies have been proposed, quarantine is the only intervention that appears to be effective in decreasing the contagion rate. Specifically designed randomized clinical trials are needed to determine the most appropriate evidence‐based treatment modality.Keywords
This publication has 126 references indexed in Scilit:
- Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal modelCell Research, 2012
- Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal AntibodyClinical Pharmacokinetics, 2012
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in PsoriasisPLOS ONE, 2012
- Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interactionAntiviral Research, 2007
- Long-term SARS Coronavirus Excretion from Patient Cohort, ChinaEmerging Infectious Diseases, 2004
- Viral Loads in Clinical Specimens and SARS ManifestationsEmerging Infectious Diseases, 2004
- Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugsBioorganic & Medicinal Chemistry, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Detection of SARS Coronavirus in Patients with Suspected SARSEmerging Infectious Diseases, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003